Protean agonists are of great pharmacological interest as their behavior may change in magnitude and direction depending on the constitutive activity of a receptor. Yet, this intriguing phenomenon has been poorly described and understood, due to the lack of stable experimental systems and design strategies. In this study, we overcome both limitations: First, we demonstrate that modulation of the ionic strength in a defined experimental set-up allows for analysis of G protein-coupled receptor activation in the absence and presence of a specific amount of spontaneous receptor activity using the muscarinic M2 acetylcholine receptor as a model. Second, we employ this assay system to show that a dualsteric design principle, that is, molecular probes, carrying two pharmacophores to simultaneously adopt orthosteric and allosteric topography within a G protein-coupled receptor, may represent a novel approach to achieve protean agonism. We pinpoint three molecular requirements within dualsteric compounds that elicit protean agonism at the muscarinic M2 acetylcholine receptor. Using radioligandbinding and functional assays, we posit that dynamic ligand binding may be the mechanism underlying protean agonism of dualsteric ligands. Our findings provide both new mechanistic insights into the still enigmatic phenomenon of protean agonism and a rationale for the design of such compounds for a G protein-coupled receptor.

A new molecular mechanism to engineer protean agonism at a G protein-coupled receptor / A. De Min, C. Matera, A. Bock, J. Holze, J. Kloeckner, M. Muth, C. Traenkle, M. De Amici, T. Kenakin, U. Holzgrabe, C. Dallanoce, E. Kostenis, K. Mohr, R. Schrage. - In: MOLECULAR PHARMACOLOGY. - ISSN 0026-895X. - 91:4(2017), pp. 348-356. [10.1124/mol.116.107276]

A new molecular mechanism to engineer protean agonism at a G protein-coupled receptor

C. Matera
Secondo
;
M. De Amici;C. Dallanoce;
2017

Abstract

Protean agonists are of great pharmacological interest as their behavior may change in magnitude and direction depending on the constitutive activity of a receptor. Yet, this intriguing phenomenon has been poorly described and understood, due to the lack of stable experimental systems and design strategies. In this study, we overcome both limitations: First, we demonstrate that modulation of the ionic strength in a defined experimental set-up allows for analysis of G protein-coupled receptor activation in the absence and presence of a specific amount of spontaneous receptor activity using the muscarinic M2 acetylcholine receptor as a model. Second, we employ this assay system to show that a dualsteric design principle, that is, molecular probes, carrying two pharmacophores to simultaneously adopt orthosteric and allosteric topography within a G protein-coupled receptor, may represent a novel approach to achieve protean agonism. We pinpoint three molecular requirements within dualsteric compounds that elicit protean agonism at the muscarinic M2 acetylcholine receptor. Using radioligandbinding and functional assays, we posit that dynamic ligand binding may be the mechanism underlying protean agonism of dualsteric ligands. Our findings provide both new mechanistic insights into the still enigmatic phenomenon of protean agonism and a rationale for the design of such compounds for a G protein-coupled receptor.
Medicine (all); Molecular Medicine; Pharmacology
Settore BIO/14 - Farmacologia
Settore CHIM/08 - Chimica Farmaceutica
2017
http://molpharm.aspetjournals.org/content/molpharm/91/4/348.full.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
Molecular Pharmacology 2017, 91, 348–356.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 966.56 kB
Formato Adobe PDF
966.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/486878
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact